Dobutamine Injection 250 mg

Dobutamine Injection 250 mg is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. 

India has many manufacturers who manufacture  Dobutamine Injection 250 mg .To know more contact us.

3s corporation is Supplier,Exporter ,Wholesaler  for Dobutamine Injection 250 mg in India.

Dobutamine contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity– A 10- to 20-mm increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients Approximately 5% of patients have had increased premature ventricular beats during infusions. These effects are dose related.

Hypotension – Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. In rare cases, however,intervention be required and reversibility may not be immediate.

Reactions at Sites of Intravenous Infusion –Phlebitis has occasionally been reported. Local inflammatory changes have been described following inadvertent infiltration. Isolated cases of cutaneous necrosis (destruction of skin tissue) have been reported.

Miscellaneous Uncommon Effects – The following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, non-specific chest pain, palpitations, and shortness of breath.

Isolated cases of thrombocytopenia have been reported.